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Abstract
DNA-methylation is an important epigenetic feature in health and disease. Methylated sequence capturing by Methyl
Binding Domain (MBD) based enrichment followed by second-generation sequencing provides the best combination of
sensitivity and cost-efficiency for genome-wide DNA-methylation profiling. However, existing implementations are
numerous, and quality control and optimization require expensive external validation. Therefore, this study has two aims: 1)
to identify a best performing kit for MBD-based enrichment using independent validation data, and 2) to evaluate whether
quality evaluation can also be performed solely based on the characteristics of the generated sequences. Five commercially
available kits for MBD enrichment were combined with Illumina GAIIx sequencing for three cell lines (HCT15, DU145, PC3).
Reduced representation bisulfite sequencing data (all three cell lines) and publicly available Illumina Infinium BeadChip data
(DU145 and PC3) were used for benchmarking. Consistent large-scale differences in yield, sensitivity and specificity between
the different kits could be identified, with Diagenode’s MethylCap kit as overall best performing kit under the tested
conditions. This kit could also be identified with the Fragment CpG-plot, which summarizes the CpG content of the
captured fragments, implying that the latter can be used as a tool to monitor data quality. In conclusion, there are major
quality differences between kits for MBD-based capturing of methylated DNA, with the MethylCap kit performing best
under the used settings. The Fragment CpG-plot is able to monitor data quality based on inherent sequence data
characteristics, and is therefore a cost-efficient tool for experimental optimization, but also to monitor quality throughout
routine applications.
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Introduction
DNA-methylation is an epigenetic process associated with gene
expression regulation. In mammalian somatic cells, it predomi-
nantly occurs at cytosines in a CpG-dinucleotide context, and it is
catalyzed by DNA-methyltransferases. In the human genome, up
to 80% of CpGs have been reported to be methylated. While this
appears to be a fixed status for most CpGs, the methylation degree
of longer stretches of DNA enriched in CpG-dinucleotides, i.e.
"CpG-islands", is more versatile and particularly associated with
transcriptional regulation, e.g. in cellular differentiation, imprint-
ing of paternal/maternal alleles and female X chromosome
inactivation [1,2]. Particularly when located in promoter or first
exon regions, CpG-island methylation has been reported to lead to
transcriptional silencing [3]. Aberrant DNA-methylation has been
associated with a plethora of diseases, including most types of
cancer, cardiovascular disease and Alzheimer’s disease [4,5,6]. In
these and other diseases, DNA-methylation studies have led to the
identification of novel biomarkers and risk factors, with clinical
applications in the diagnostic, prognostic and pharmacogenomics
fields [7,8,9,10,11].
Until recently, applications were predominantly limited to locus
specific methylation assays, for examples see references [9,12], but
the advent of high-throughput technologies has introduced the
possibility of genome-wide DNA-methylation profiling. Most
methodologies are based on the application of bisulfite treatment
to genomic DNA, which chemically converts unmethylated
cytosines to uracil, but leaves methylated cytosines intact. Uracil
corresponds to thymine with respect to its basepairing behavior.
After sequencing, DNA-methylation status differences are implied
by sequence differences as only unmethylated cytosines will be
observed as thymines [13]. Whole genome sequencing of bisulfite
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treated DNA is possible, but as sufficient coverage over the full
genome should be obtained for quantification, costs are currently
even higher than for normal whole genome sequencing. Methods
such as reduced representation bisulfite sequencing (RRBS) [14]
therefore reduce the proportion of the genome to be sequenced.
Alternatively, relatively inexpensive bead array-based methods
have been developed for bisulfite treated DNA (Illumina Infinium
BeadChip) [15]. Besides the traditional array problems, even
though the novel 450k Infinium BeadChips covers a major part of
the human DNA-methylome [16], the genome-wide character and
quality of these assays are inherently limited by the probe design.
The major alternative for bisulfite treated DNA-characteriza-
tion is the purification of methylated DNA-fragments followed by
sequencing, which allows for a cost-efficient (order of magnitude,
103 J), genome-wide approach. Although there are several
possibilities with often complementary strengths [17], specific
antibodies for methylated DNA immuno-precipitation (MeDIP)
[18,19] are most widely used. However, the application of methyl-
CpG binding domain (MBD) proteins [20,21] for affinity based
purification is believed to be inherently better due to the biological
origin of the MBD. A recent study demonstrated that, when total
coverage is sufficient, MBD-seq (also called MethylCap-seq or
MiGS) is generally more sensitive than MeDIP-seq [22,23] and
methylation specific microarrays (after bisulfite treatment) [22]. A
greater sensitivity for MBD compared to MEDIP was also
confirmed in a microarray based study [24]. Therefore, until
further optimization of sequencing technologies allows for a cost-
efficient whole-genome sequencing of bisulfite treated DNA or
direct detection of methylated cytosines at base-resolution, MBD-
seq might easily become the most widely used methodology.
Lately, several commercial ‘DNA-methylation capturing’ kits
for MBD-based affinity purification have been developed, typically
with different options regarding salt concentration for the elution
step. For an optimal analysis it is important to use the most
sensitive and specific methodology available. However, indepen-
dent information about the yield, specificity and sensitivity of these
kits (and the different options) is completely absent, and the only
manner to assess this is to use expensive external validation, e.g. by
bisulfite sequencing. In addition, there are no objective measures
to identify aberrant profiles which should be excluded from further
analysis. Indeed, while MBD-seq is rapidly gaining importance,
there is a need for a straightforward quality evaluation tool, cf. the
diagnostic plots for microarrays e.g. [25]. The Fragment CpG-
plot, depicting the CpG content of the captured fragments, has the
potential to be such a tool.
Therefore, we evaluated five commercially available MBD-
based DNA-methylation purification kits for combination with
next generation sequencing, and results were benchmarked by two
sets of data generated using other platforms (RRBS and Infinium
HumanMethylation27 BeadChips). In order to evaluate the
consistency of the results, conclusions were compared between
three different cell lines (HCT15, DU145 and PC3). Subsequently,
it was assessed whether the same conclusions could be obtained
based solely on the Fragment CpG plot.
Materials and Methods
Sample preparation
We used 3 different human cell lines: DU145, PC3 (prostate
cancer) and HCT15 (colon cancer). Cell lines PC3 and HCT15
were purchased from ATCC and were collected at passage 3. Cell
line DU145 was purchased from CHU Lie`ge and cells were
collected at passage 9. Genomic DNA was extracted from these
cell lines with the Easy DNA kit (Invitrogen K1800-01) according
to protocol #4. The DNA concentration was measured on a
NanoDrop ND-1000 (Thermo Scientific, Wilmington, North
Carolina, USA).
DNA fragmentation
Fragmentation of the genomic DNA was performed on Covaris
S2 (Covaris, Woburn, Massachusetts, USA) with following
settings: duty cycle 10%, intensity 5, 200 cycles per burst during
180 seconds to obtain fragments with an average length of 200 bp.
The power mode was frequency sweeping, temperature 6–8uC
and water level 12. 500 ng was loaded in 130 ml TE (1:5) in a
microtube with AFA intensifier (Covaris, Woburn, Massachusetts,
USA). Length of the fragments was analyzed on a DNA High
Sensitivity chip on an Agilent 2100 (Agilent Technologies, Santa
Clara, California, USA). Concentration was determined on a
FluoStar Optima plate reader (BMG Labtech, Offenburg,
Germany) with the Quant-iTTM PicogreenH dsDNA assay kit
(Invitrogen P7589, Merelbeke, Belgium) on 480/520 nm.
Kit selection and methylated DNA capturing
All MBD-based capturing kits commercially available at the
time of study initiation were included in this study. Tested kits,
with indication of used MBDs (although typically recombinant
forms), were: MethylMagnetTM mCpG DNA isolation kit
(MBD2b) (Ribomed MM101-K, Carlsbad, California, USA),
MethylCollectorTM (MBD2b) and MethylCollectorTM Ultra
(MBD2b and MBD3L1) (Active Motif 55005, Carlsbad, Califor-
nia, USA), MethylCapTM kit (MBD from MeCP2) (Diagenode
AF-100-0048, Lie`ge, Belgium), MethylMinerTM Methylated DNA
Enrichment Kit (MBD2) (Invitrogen ME10025, Merelbeke,
Belgium). For the remainder of the manuscript, these kits are
referred to as respectively MethylMagnet, MethylCollector,
MethylCollector Ultra, MethylCap and MethylMiner kits. Fre-
quency of use, as estimated by Google Scholar citations (http://
scholar.google.com) at the beginning of January 2013, were
roughly 50 times for the MethylCollector kits, 25 times for
MethylCap and 50 times for MethylMiner, whereas only 3
references to the MethylMagnet kit could be found.
For each cell line, 200 ng of the fragmented DNA was subjected
to every kit following the manufacturer’s recommended protocol
using the highest salt concentration and with the only exception
that short (,=5 min) centrifugation and rotation steps were
performed at room temperature (instead of 4uC) for the Methyl-
Cap kit. Quantification of the captured DNA was performed with
the FluoStar Optima plate reader (BMG Labtech) with the Quant-
iTTM PicogreenH dsDNA assay kit (Invitrogen P7589) on 480/
520 nm. The eluted DNA was purified using a MinElute Reaction
Cleanup kit (Qiagen 28204, Germantown, Maryland, USA).
Illumina library preparation
As kit yields were often too low for reliable detection (Table 1),
for each captured fraction, the complete amount of purified DNA
was used for library preparation, which was performed with a
modified ‘multiplexed paired-end ChIP protocol’ (Illumina, San
Diego, California, USA). The NEBNextH DNA Sample Prep
Master Mix Set 1 (New England BioLabs (NEB) E6040, Ipswich,
Massachusetts, USA) was used in combination with the Multi-
plexing Sample Preparation Oligo Kit (Illumina PE-400-1001).
For each kit, a different barcode was used for each cell line,
implying that observed effects cannot be attributed to different
barcode sequencing efficiencies.
Methyl Binding Domain Enrichment Kit Evaluation
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Library amplification and sequencing
22ml of DNA was subjected to PCR following the Illumina
Library Amplification Index Protocol (Illumina) with 21 cycles of
PCR amplification. PCR products were purified on Qiaquick
PCR Purification columns (Qiagen 28101) and eluted in 50ml
elution buffer (1:5). Next, the libraries were concentrated in a
rotary evaporator (Jouan 11176740, St-Herblain, France) to 10ml
and assessed using an Agilent 2100 High Sensitive DNA chip
(Agilent Technologies). The concentration was determined by
qPCR with a PhiX index3 standard solution (Illumina PE-400-
1002). Only then, libraries were pooled per four (2ml aliquots at
10nM of each individual library), and each of these pools was used
for NaOH denaturation. After denaturation, pools were diluted to
10pM and used for sequencing on an Illumina Genome Analyzer
IIx following the Illumina protocol: ‘performing a multiplexed
paired-end run’ (2 times 45 cycle). As such, sequencing was
performed with 4 libraries per lane and one control lane with PhiX
index3 control (Illumina PE-400-1002).
Data processing and the fragment CpG plot
For each cell line and kit combination, paired-end reads were
mapped using BOWTIE [26]. Only those fragments that mapped
uniquely within a 400 bp of each other in the human reference
genome (NCBI build 37) were retained. Here, we define a
"mapped fragment" as the reference genome sequence corre-
sponding with a mapped fragment, including both sequenced ends
and the region in between. Further data-analysis was performed
using R 2.15.0.
The Fragment CpG plot depicts the CpG content of the
captured fragments, i.e. the frequency of mapped fragments with a
certain CpG content. For the creation of this plot, the amount of
CpGs was counted for each obtained mapped fragment. Suppose
that, for a specific sample (i.e. cell line-kit combination), there are
Fi fragments with i CpGs (i=0, 1, 2,...), yielding a total of Si(Fi)
fragments for that sample. The Fragment CpG plot then depicts
the normalized Fi counts, i.e. Fi/Si(Fi), as a function of i, for that
sample. The R-script for this quality control tool is available upon
request.
Bisulfite sequencing and Infinium BeadChip data
Reduced representation bisulfite sequencing [14] was per-
formed by BaseClear (Leiden, the Netherlands), using the
EpiQuest DNA Methylation Analysis Platform (http://www.
baseclear.com/dna-sequencing/next-gen-sequencing/epiquest-5-
mc-analysis/) yielding 2650 paired end bisulfite sequence reads,
with total coverages of 27.9, 39.2 and 51.0 million paired reads for
respectively HCT15, PC3 and DU145 which were further
processed using a custom pipeline (BaseClear). For each CpG,
intensities for both strands of the genome were summed for
comparison with MBD-seq data.
Independent Infinium HumanMethylation27 BeadChip data,
as reported by Kim et al. [27], were downloaded from the Gene
Expression Omnibus (GEO, accession number: GSE23388, data
were already quantile normalized). R-package IlluminaHuman-
Methylation27k.db and GEO dataset GPL8490 were used to
identify the exact location of each CpG assessed by the individual
probes. The UCSC liftOver tool (http://genome.ucsc.edu/cgi-
bin/hgLiftOver) with standard settings was applied to convert
CpG-loci from human reference genome build 36 to build 37, with
a success rate of 99.95%.
Availability of generated data
The data sets supporting the results of this article are available in
the GEO repository [GSE42790; http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=bjslvemcuqkysju&acc=GSE42790].
Results
In the first part of the results section, the yield of the different
kits (see Table 1) is assessed as a first indication of kit and
Table 1. MBD-based kit yield, as physical yield, and as number of raw fragments, uniquely mapped fragments and non-duplicate
uniquely mapped fragments after sequencing, for each cell line.
Cell line MBD-based kit
a. Physical
yield (ng)
b. Number of
sequenced fragments*
c. Total uniquely mapped
fragments (% of b)
d. Non-duplicate uniquely
mapped fragments (% of c)
HCT15 MethylMagnet 4.85 1,805,640 734,996 (40.7) 60,194 (8.2%)
MethylCollector N/A 3,664,676 1,677,359 (45.8) 266,922 (15.9%)
MC Ultra 6.30 3,576,381 1,514,976 (42.4) 655,819 (43.3%)
MethylCap 9.38 11,531,844 6,632,940 (57.5) 3,916,243 (59.0%)
MethylMiner 24.80 15,315,046 9,759,129 (63.7) 7,387,361 (75.7%)
DU145 MethylMagnet 1.75 155,564 81,179 (52.2) 10,054 (12.4)
MethylCollector N/A 230,880 120,948 (52.4) 29,656 (24.5)
MC Ultra N/A 146,551 79,066 (54.0) 30,357 (38.4)
MethylCap 4.30 2,733,079 1,483,445 (54.3) 825,370 (55.6)
MethylMiner 25.80 6,700,917 4,259,089 (63.6) 2,968,040 (69.7)
PC3 MethylMagnet 2.00 1,500,615 742,693 (49.5) 243,273 (32.8)
MethylCollector N/A 277,756 155,694 (56.1) 85,153 (54.7)
MC Ultra 2.40 1,363,234 1,090,164 (80.0) 580,789 (53.3)
MethylCap 8.45 2,763,144 1,672,190 (60.5) 952,757 (57.0)
MethylMiner 48.30 3,103,308 2,179,903 (70.2) 2,102,540 (96.5)
MC Ultra indicates MethylCollector Ultra, and N/A indicates not available due to too low amounts for accurate measurements.
*Due to the paired-end sequencing, one fragment corresponds with 2 reads.
doi:10.1371/journal.pone.0059068.t001
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experiment quality, followed by an exploratory analysis of the
DNA methylation patterns for some loci. The second part consists
of an evaluation of sensitivity and specificity of the different kits,
using two sources of independent data. Finally, the conclusions
from these analyses are compared with those generated by the
fragment CpG plot.
Kit yield evaluation
For each condition (kit and cell line), 200 ng of DNA was used,
which is appropriate according to all the manufacturers’ instruc-
tions and realistic in a clinical setting. Although only indirectly
associated with data quality, the yield of a given kit or enrichment
methodology is a very important characteristic. The most direct
measure to assess yield is to measure the amount of DNA isolated
for each condition (kit/cell line combination). However, as these
amounts were often too low for accurate measurements (Table 1),
we also assessed the number of sequenced fragments. As there will
be a major impact of the other libraries sequenced within the same
lane, this number can only be considered as a semi-quantitative
measure.
The sequencing protocol might result in multiple fragments
uniquely mapping on exactly the same location in the genome,
and therefore most likely originating from the same sequence
(duplicates). Low kit yields associated with high non-duplicate
fractions would therefore most likely indicate decreased sequenc-
ing (and not kit) efficiency. Low yields associated with low non-
duplicate fractions on the other hand clearly indicate the low kit
efficiency as the underlying cause: low numbers of fragments were
pre-amplified resulting in low numbers of, predominantly dupli-
cate, fragments. Table 1 therefore also summarizes the number of
non-duplicate, mappable fragments. Overall, these numbers
reflect the directly measured kit yield (in ng), also in Table 1,
although it should be noted that the relationship is clearly not
linear.
Table 1 demonstrates that there are large differences between
cell lines (samples), but even more between kits. The MethylMiner
kit resulted in the highest yield, followed by the MethylCap kit.
Both MethylCollector kits and the MethylMagnet kit are featured
by very low yields when starting from 200 ng input material. It is
clear that the different yields are inherent kit characteristics, and
will certainly have an impact on data quality: since higher yields
might be caused by a higher sensitivity, but also by a lower
specificity, these features are evaluated in the next paragraphs. For
the remainder of the results section, for each individual condition,
multiple fragments mapping to the exact same locations on the
human genome (duplicate fragments) were considered as origi-
nating from, and further processed as, a single fragment. In a first
attempt to assess the sensitivity and specificity of the different kits,
the generated DNA methylated patterns are visually inspected for
a selected set of loci.
Exploratory analysis: comparison with RRBS results for
selected set of loci
The DNA-methylation status of the promoter regions of 4
selected loci was compared between the different kits and samples
using the RRBS results as gold standard. Figure 1 depicts the
MBD-seq (mapped putatively methylated fragments) and RRBS
(% methylation) results for Igfbp3 (panel A), Tert (panel B), Epb41l3
(panel C) and Socs3 (panel D) for all three cell lines. Figure 1
demonstrates that, in general, MBD-seq adequately detects
methylation when a certain number of CpGs is sufficiently
methylated. However, there is variation between kits that cannot
be solely attributed to yield differences. For example, the
MethylMiner kit often suggests presence of DNA-methylation,
e.g. in the Igfbp3 and Socs3 promoters of DU145, for which RRBS
evidence is poor at most, implying low specificity. Also for
MethylMagnet, specificity often appears to be low, e.g. in the
Igfbp3 and Epb41l3 promoters for PC3. The MethylCap and both
MethylCollector kits appear to be featured by a reasonable
sensitivity and specificity, but yield differences complicate a finer
comparison. More advanced, genome-wide analyses are therefore
required.
Genome-wide kit comparison with independent
validation data
MBD-seq based data were compared with RRBS results for the
three cell lines. In order to obtain sufficient resolution, only loci
with RRBS coverages.=20 were considered. Direct evaluation
of sensitivity and specificity of the kits is complicated by the major
yield differences between kits, e.g. higher yields are typically
associated with higher sensitivity and/or lower specificity. Here, a
yield independent approach is envisaged by plotting the fractions of
mapped fragments corresponding with specific RRBS derived
CpG methylation degrees (binned per 2%), e.g. a Y-axis value of
0.03 for RRBS values between 0 and 0.02 for a specific kit implies
that 3% of the mapped fragments for that kit contain virtually
unmethylated (between 0 and 2%) CpGs as determined by RRBS.
As the fractions sum to one for each of the kits, the profiles are
independent of the major yield differences. In addition, a
background profile is plotted which depicts all loci assessed by
RRBS, i.e. the full pool of loci that can be captured by the
different kits (Figure 2, A–C). Division by the background profile
fractions for the corresponding RRBS methylation degrees further
clarifies the result (Figure 2, D–F). Note that the plots are CpG-
oriented: fragments may contain several CpGs assessed by RRBS,
and might therefore belong to several of the fractions in the plot.
However, these dependencies between data points are negligible
compared to the massive amounts of data depicted.
Except for MethylMiner, all kits captured only low fractions of
alleles featured by absence of methylation, whereas there was a
clear enrichment for heavily methylated alleles (Figure 2). Under
the evaluated conditions, the MethylMiner profile mimics the
background profile, i.e. the high yield for this kit (Table 1) can be
explained by the very high fraction of noise captured. It is clear
from Figure 2 that the MethylCap and MethylCollector kit exhibit
the lowest fraction of fragments with RRBS methylation degrees
> 0 and are therefore featured by the highest specificity, followed
by the MethylCollector Ultra and MethylMagnet kits. Sensitivity
can here be defined as a kit’s capacity to capture fragments with
lower methylation degrees, and can be assessed as the point where
a kit’s profile is consistently higher (enriched) compared to the
background profile. For all three cell lines, the MethylCap kit
appears to be featured by the highest sensitivity. Although less
clear for DU145 (lower resolution due to lower yields for several
kits, cf. Table 1), the MethylCap kit is followed by the
MethylCollector, MethylCollector Ultra and MethylMagnet kits
regarding sensitivity (ignoring the MethylMiner profile). Note that
the peak heights for RRBS methylation degrees > 1 are less
informative as the plotting of fractions implies that more narrow
peaks are also typically higher.
As an additional validation step, the MBD data obtained with
the different kits were also compared with Infinium Human-
Methylation27 BeadChip results, independently generated by Kim
et al. [27], for cell lines DU145 and PC3. Here, it should be stated
that the use of external methylation data entails the possibility that
different experimental conditions between different labs could
already have introduced changes in methylation, but that this will
have equal effects on each evaluated kit. Similar plots were created
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Figure 1. Exploratory comparison of MBD-seq and RRBS data. Visual comparison of MBD-seq results for MethylMagnet (MMag),
MethylCollector (MCol), MethylCollector Ultra (MCU), MethylCap (MCap) and MethylMiner (MMin) with RRBS data for the promoter regions of four
selected loci, i.e. Igfbp3 (panel A, chromosome 7, depicted from position 45959883 to 45962146), Tert (panel B, chromosome 5, 1293850 to 1296219),
Epb41l3 (panel C, chromosome 8, 5628365 to 5630973) and Socs3 (panel D, chromosome 17, 76354158 to 76357420). CpGs assessed by RRBS are
indicated as vertical red (fraction methylated)/grey (fraction unmethylated) bars. Note that RRBS only assesses the methylation status of a (sometimes
variable) subfraction of CpGs.
doi:10.1371/journal.pone.0059068.g001
Figure 2. Yield independent genome-wide kit evaluation using RRBS data for external validation. Fractions of mapped MBD-seq
fragments corresponding with specific RRBS methylation degrees (binned per 2%) for the different cell lines (A, HCT15; B, DU145; C, PC3) and kits
(violet, MethylMagnet; yellow, MethylCollector; blue, MethylCollector Ultra (MC Ultra); red, MethylCap; green, MethylMiner) with indication of the
background profile (black, fractions of all RRBS values measured for specific cell line). Additionally, the same fractions after division by the
corresponding background profile fractions are plotted (D, HCT15; E, DU145; F, PC3).
doi:10.1371/journal.pone.0059068.g002
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as for the RRBS data, but using Infinium beta-values (binned per
5%) as measure for methylation degrees (Figure 3). Overall, very
similar conclusions as for the comparison with RRBS data can be
made. For these cell lines, the highest specificity could be observed
for MethylCap, followed by MethylCollector, MethylCollector
Ultra and MethylMagnet, whereas the MethylMiner profile again
reveals lack of sensitivity and specificity. The largest sensitivity
(profile consistently above background) is again observed for
MethylCap. Although the ranking of the other kits is less clear,
most likely due to the lower resolution of the Infinium assays
(about 60 times more loci were assessed by RRBS than by the
BeadChips, data not shown), also here both MethylCollector kits
appear to be more sensitive than the MethylMagnet kit.
Sensitivity and specificity based on CpG-content of the
mapped fragments: the Fragment CpG-plot
Since MBD kits theoretically only capture methylated cytosines
in a CpG-dinucleotide context, the CpG-content profile of the
mapped fragments might be used as a proxy for sensitivity and
specificity. Figure 4 depicts the percentages of sequences for each
kit corresponding with a specific CpG-count for the HCT15 cell
line. This type of diagnostic plot, here coined the "Fragment CpG-
plot", therefore also adjusts for yield differences. This plot is similar
to Figures 2A–C and 3A–B but depicts fractions of reads as a
function of CpG-content of captured reads instead of indepen-
dently assessed methylation degrees. Figure 4 suggests that the
MethylCap and MethylCollector kits are featured by the highest
specificity, i.e. lowest fraction of non CpG containing fragments,
followed by the MethylCollector Ultra and MethylMagnet kit.
Also here, the MethylMiner profile exhibits low specificity, but also
no additional CpG containing peak, indicating low sensitivity.
Sensitivity, i.e. detection of loci with low degrees of methylation,
can here be approximated as the amount of captured fragments
with low (but non zero) amounts of CpGs. The MethylCap kit
profiles demonstrate peaks with maxima at around 5 CpGs/
sequence, which suggests the highest sensitivity, followed by the
MethylCollector, MethylCollector Ultra and MethylMagnet kits
where more CpGs were required. Note that for the latter kit,
profiles tended to vary between samples. Extremely low yield
Figure 3. Yield independent genome-wide kit evaluation using Infinium HumanMethylation27 BeadChip data for external
validation. Fractions of mapped MBD-seq fragments corresponding with specific Infinium methylation degrees (binned per 5%) for two cell lines (A,
DU145; B, PC3) and all kits (violet, MethylMagnet; yellow, MethylCollector; blue, MethylCollector Ultra (MC Ultra); red, MethylCap; green, MethylMiner)
with indication of the background profile (black, fractions of all Infinium methylation values measured for specific cell line). Additionally, the same
fractions after division by the corresponding background profile fractions are plotted (C, DU145; D, PC3).
doi:10.1371/journal.pone.0059068.g003
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(DU145, Table 1) or presence of noise fractions not assessed by
RRBS and Infinium (PC3) are probable causes.
Overall, however, results are very consistent between Fragment
CpG-plot and independent validation data (RRBS, Infinium
BeadChips) derived sensitivity and specificity, indicating that the
former can indeed be used as a very straightforward tool for
quality evaluation.
Discussion
MBD-seq has a clear potential to become the most widely used
methodology for completely genome-wide methylation studies
until the advent of more appropriate and particularly cost-efficient
sequencing technologies. Several protocols and commercial kits for
MBD-based capturing of methylated fragments are currently
available, but there is a general lack of independent information
on yield, sensitivity and specificity of the different methodologies.
In addition, there are no quality diagnostic tools for the
identification of aberrant sequencing profiles, cf. the diagnostic
plots for microarray quality control [25]. In this study, the quality
of commercially available kits was evaluated using external
validation data and inherent sequence data characteristics. The
results overall confirmed the necessity of quality control.
Yield was a first major factor of difference between kits. It is
clear that yield is a crucial parameter as it affects the number of
MBD capturing steps (with associated cost) and amounts of
required (often valuable) sample to obtain the necessary DNA
quantities for high coverage sequencing. Therefore, yield should
always be taken into consideration when comparing different kits
and experimental conditions. Yield is closely entangled with
sensitivity and specificity, complicating the assessment of the latter.
Ideally, equal quantities of captured DNA by the kits would have
been used for sequencing, which would at least in theory have
allowed for a yield independent comparison of the kits’ sensitivity
and specificity. However, quantities were too low for several kits
(Table 1) to ensure that this approach would have been successful.
In addition, it should be noted that coverage differences between
samples would have been observed anyway due to variable
sequencing efficiencies between lanes and samples, implying that
some sort of normalization is always required. Therefore, we opted
to sequence all of the material obtained for each of the kits, and to
use a data-analytical approach that is unbiased by yield
differences. Indeed, relative fractions corresponding with indepen-
dently determined methylation degrees or with CpG-content were
studied. This approach was very successful as clearly reproducible
results were obtained, although extremely low amounts of mapped
fragments often resulted in more variable, lower resolution plots
that were harder to interpret. Whereas this implies that a minimal
coverage per condition is required for quality control, it should be
noted that coverages of several 100.000 mapped fragments are
certainly sufficient for Fragment CpG-plot assisted quality control,
implying relatively low cost for this type of experimental
optimization (compared to the typical biomarker studies where
millions of fragments are required).
The different analyses identified the MethylCap kit as the
overall best kit due to a consistent combination of high yield,
sensitivity and specificity. It should be noted that the high
sensitivity of the MethylCap kit also allows for capturing of low
CpG-density fragments, which have been reported to be
biologically more relevant [23,24]. The MethylMiner kit, with
an even higher yield, demonstrates a general lack of specificity
with the used settings, although results for this kit will most likely
greatly improve by not including the low-salt elution fraction. Both
MethylCollector kits are characterized by lower yields and
sensitivity than MethylCap. Based on yield and sensitivity, the
MethylCollector Ultra kit performs slightly better than the original
MethylCollector kit, which is currently no longer available.
Finally, even with some aberrant Fragment CpG-plots, it is clear
that the MethylMagnet kit was featured by lower yield, sensitivity
and specificity. Although validation by an independent laboratory
is indispensable, and other salt elution procedures could have a
major impact on the obtained data, results indicate that, of the
Figure 4. Fragment CpG-plots. Fractions of mapped MBD-seq
fragments with different CpG-counts for cell lines HCT15 (A), DU145 (B)
and PC3 (C) for the different kits: MethylMagnet (violet), MethylCollector
(yellow), MethylCollector Ultra (MC Ultra, blue), MethylCap (red) and
MethylMiner (green).
doi:10.1371/journal.pone.0059068.g004
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MBD-based kits under study, the MethylCap kit performs best,
followed by the MethylCollector kits. Whereas these conclusions
are based on two sources of independent validation data, the
Fragment CpG-plots allowed us to perform this ranking solely
based on the generated sequence data. This demonstrates that the
value of this study surpasses the limitations imposed by the
restricted set of experimental conditions evaluated.
Interestingly, MethylCap is the only kit for which the MBD
originates from MeCP2, while this is MBD2 for the other kits.
Although both proteins bind methylated DNA in a very similar
manner, they exhibit some sequence specificity (around the mCpG)
and MBD2 was reported to show a higher binding affinity than
MeCP2 [28,29]. However, it remains unclear to what extent
overall sensitivity and specificity are affected by the fact that only
(specific recombinant forms of) the MBD-domains are used in the
kits.
As it is costless and straightforward, we suggest to use the
Fragment CpG-plot to monitor quality for experimental optimi-
zation, but also during standard applications to identify aberrant
profiles. Note that (variants of) Fragment CpG-plots have already
been used in other studies, e.g. [22,23], underscoring the intuitive
character of these diagnostic plots. However, this is the first study
performing an objective evaluation and independent validation of
their practical use.
It should be taken into account that there are several limitations
to the Fragment CpG-plot. First, longer fragments will (on
average) consist of more CpGs, implying that the degree of
DNA-fragmentation prior to capturing will affect the Fragment
CpG-plots. While the impact is limited for the identification of
aberrant profiles, or for an in house experimental optimization (cf.
this study), it will certainly complicate comparisons between
different studies. To obtain the most reliable Fragment CpG-plots,
one should always attempt to obtain fragments as short as possible,
as long as it does not affect capturing, sequencing and mapping
yields. Since this will also increase the resolution of the sequencing
methodology itself, i.e. the exact methylated cytosines can be more
accurately identified, this is an objective aim that will results in an
overall improvement of the data. A second putative limitation is
that Fragment CpG-plots are less suitable for MeDIP-experiments,
as the latter will also measure non-CpG-methylation. However,
certainly in a human context, non-CpG-methylation is limited: it
particularly occurs in embryonic (and other) stem cells, and even
in these cells it has been estimated to compose only one quarter of
the total amount of methylated cytosins [30]. Therefore, Fragment
CpG-plots will most likely also be suitable to identify aberrant
MeDIP profiles or to perform comparative MeDIP studies.
However, in other species with more prominent non-CpG-
methylation, these diagnostic plots might be insufficient. A final
limitation is the fact that Fragment CpG-plots cannot be used for
short single-end read sequencing data. However, paired-end
sequencing is the current standard for enrichment based
sequencing experiments as it ensures more accurate mapping.
Fragment CpG-plots are also suitable for single-end reads that are
adequately long, preferably encompassing the full captured
fragment, which will become more important in the future.
In conclusion, DNA-methylation is increasingly gaining impor-
tance in clinical practice, both from a diagnostic, prognostic and
pharmacogenomic viewpoint. Currently, MBD-based sequencing
is the most cost-efficient method for the putative genome wide
identification of DNA-methylation. Here, we demonstrated major
differences in yield, sensitivity and specificity of commercially
available kits, illustrating the need for objective quality measures
for this type of experiments. Independent validation is however not
always necessary, as Fragment CpG-plots already provide us with
a good overview of sensitivity and specificity. Indeed, solely based
on this diagnostic plot, it was possible to identify MethylCap as the
best kit under the conditions used in this study. Reporting this
diagnostic plot, together with yield, facilitates experimental quality
evaluation, for comparative studies but certainly also for individual
experiments and it might be considered to establish this as a
standard practice.
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